,,,,MSC25:MEF75/MSC75:MEF25,MSC50:MEF50/MSC75:MEF25,MSC25:MEF75/MSC50:MEF50,,,,,,
Reactome pathways,number,overUnder,pvalue,fdr,fdr,fdr,,,,,,
Metabolism of proteins (R-HSA-392499),65,+,6.42E-01,9.25E-01,1.52E+00,3.49E+00,,,,,,
Immune System (R-HSA-168256),54,+,5.52E-01,8.84E-01,9.17E-01,1.00E+00,,,,,,
Signal Transduction (R-HSA-162582),51,+,9.25E-01,9.66E-01,9.26E-01,9.93E-01,,,,,,
Metabolism (R-HSA-1430728),50,+,3.08E-01,6.64E-01,8.89E-01,9.93E-01,,,,,,
Post-translational protein modification (R-HSA-597592),39,-,8.38E-01,9.34E-01,9.54E-01,2.40E+00,,,,,,
Innate Immune System (R-HSA-168249),33,+,2.31E-01,1.01E+00,7.80E-01,1.00E+00,,,,,,
Developmental Biology (R-HSA-1266738),31,+,2.98E-01,9.40E-01,7.84E-01,1.11E+00,,,,,,
Vesicle-mediated transport (R-HSA-5653656),31,+,7.33E-01,9.36E-01,8.79E-01,1.62E+00,,,,,,
Extracellular matrix organization (R-HSA-1474244),25,+,1.42E-01,1.13E+00,9.72E-01,1.01E+00,,,,,,
Membrane Trafficking (R-HSA-199991),25,+,7.09E-01,9.41E-01,7.87E-01,1.10E+00,,,,,,
Disease (R-HSA-1643685),24,-,6.95E-01,9.38E-01,9.41E-01,9.42E-01,,,,,,
Neutrophil degranulation (R-HSA-6798695),23,+,3.93E-01,7.58E-01,9.38E-01,1.03E+00,,,,,Analysis Type:,PANTHER Enrichment Test (release 20181003)
Axon guidance (R-HSA-422475),23,+,4.12E-01,7.72E-01,9.83E-01,1.02E+00,,,,,Annotation Version and Release Date:,Reactome version 65 Released 2018-06-12
Hemostasis (R-HSA-109582),22,-,7.75E-01,9.29E-01,8.84E-01,1.03E+00,,,,,Analyzed List:,test.txt (Homo sapiens)
Degradation of the extracellular matrix (R-HSA-1474228),18,+,9.20E-02,1.31E+00,1.44E+00,9.92E-01,,,,,Correction:,FDR
Signaling by Receptor Tyrosine Kinases (R-HSA-9006934),16,+,6.81E-02,1.34E+00,6.70E-01,1.00E+00,,,,,,
Adaptive Immune System (R-HSA-1280218),16,-,2.91E-01,9.20E-01,7.45E-01,1.00E+00,,,,,,
"Platelet activation, signaling and aggregation (R-HSA-76002)",16,+,9.50E-01,9.79E-01,7.68E-01,9.37E-01,,,,,,
Cytokine Signaling in Immune system (R-HSA-1280215),16,-,9.70E-01,9.91E-01,8.69E-01,1.00E+00,,,,,,
Transport of small molecules (R-HSA-382551),15,-,6.47E-02,1.40E+00,8.94E-01,9.86E-01,,,,,,
Signaling by Rho GTPases (R-HSA-194315),15,+,5.72E-01,9.04E-01,8.23E-01,1.12E+00,,,,,,
Post-translational protein phosphorylation (R-HSA-8957275),15,-,7.03E-01,9.44E-01,8.33E-01,1.04E+00,,,,,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) (R-HSA-381426),15,-,7.03E-01,9.42E-01,8.31E-01,9.81E-01,,,,,,
Gene expression (Transcription) (R-HSA-74160),14,-,5.26E-02,1.22E+00,9.29E-01,1.04E+00,,,,,,
ECM proteoglycans (R-HSA-3000178),14,+,2.11E-01,9.78E-01,9.02E-01,1.65E+00,,,,,,
Asparagine N-linked glycosylation (R-HSA-446203),14,+,5.91E-01,9.14E-01,8.89E-01,4.00E+00,,,,,,
Translation (R-HSA-72766),14,+,7.12E-01,9.45E-01,6.62E-01,1.62E+00,,,,,,
Platelet degranulation  (R-HSA-114608),14,+,8.18E-01,9.21E-01,7.80E-01,1.00E+00,,,,,,
Response to elevated platelet cytosolic Ca2+ (R-HSA-76005),14,+,8.18E-01,9.19E-01,7.78E-01,1.02E+00,,,,,,
Integrin cell surface interactions (R-HSA-216083),13,+,1.05E-02,7.04E+00,1.30E+00,1.45E+00,,,,,,
Generic Transcription Pathway (R-HSA-212436),13,-,6.52E-02,1.37E+00,9.50E-01,1.28E+00,,,,,,
RNA Polymerase II Transcription (R-HSA-73857),13,-,6.52E-02,1.33E+00,6.70E-01,1.04E+00,,,,,,
Apoptosis (R-HSA-109581),13,-,2.55E-01,1.01E+00,6.68E-01,9.92E-01,,,,,,
Programmed Cell Death (R-HSA-5357801),13,-,2.55E-01,1.00E+00,7.82E-01,1.04E+00,,,,,,
Metabolism of amino acids and derivatives (R-HSA-71291),13,+,3.91E-01,7.57E-01,7.80E-01,1.04E+00,,,,,,
Metabolism of carbohydrates (R-HSA-71387),13,-,7.68E-01,9.28E-01,8.64E-01,9.88E-01,,,,,,
Metabolism of RNA (R-HSA-8953854),13,-,8.02E-01,9.20E-01,9.21E-01,1.01E+00,,,,,,
Collagen formation (R-HSA-1474290),12,+,3.10E-01,6.65E-01,7.51E-01,1.10E+00,,,,,,
Signaling by Interleukins (R-HSA-449147),11,-,3.70E-01,7.24E-01,9.67E-01,1.12E+00,,,,,,
Apoptotic execution phase (R-HSA-75153),11,-,4.18E-01,7.79E-01,7.22E-01,1.13E+00,,,,,,
Apoptotic cleavage of cellular proteins (R-HSA-111465),11,-,4.18E-01,7.77E-01,7.68E-01,1.10E+00,,,,,,
Metabolism of lipids (R-HSA-556833),11,+,4.26E-01,7.88E-01,8.78E-01,1.02E+00,,,,,,
Muscle contraction (R-HSA-397014),11,-,6.42E-01,9.26E-01,9.23E-01,9.74E-01,,,,,,
Cell Cycle (R-HSA-1640170),11,-,6.67E-01,9.19E-01,9.21E-01,1.01E+00,,,,,,
RHO GTPase Effectors (R-HSA-195258),11,+,7.90E-01,9.32E-01,9.90E-01,1.02E+00,,,,,,
Collagen biosynthesis and modifying enzymes (R-HSA-1650814),10,+,1.46E-01,1.01E+00,1.42E+00,9.88E-01,,,,,,
Cellular responses to stress (R-HSA-2262752),10,-,1.53E-01,1.04E+00,1.37E+00,1.03E+00,,,,,,
Cellular responses to external stimuli (R-HSA-8953897),10,-,1.53E-01,1.03E+00,8.68E-01,1.04E+00,,,,,,
Collagen degradation (R-HSA-1442490),10,+,2.27E-01,1.00E+00,8.65E-01,9.85E-01,,,,,,
Assembly of collagen fibrils and other multimeric structures (R-HSA-2022090),9,+,4.25E-01,7.88E-01,9.53E-01,1.08E+00,,,,,,
Non-integrin membrane-ECM interactions (R-HSA-3000171),9,+,4.39E-01,8.04E-01,8.91E-01,1.00E+00,,,,,,
"Cell Cycle, Mitotic (R-HSA-69278)",9,-,4.98E-01,8.44E-01,7.65E-01,2.42E+00,,,,,,
ER to Golgi Anterograde Transport (R-HSA-199977),9,+,6.53E-01,9.32E-01,7.79E-01,2.26E+00,,,,,,
Transport to the Golgi and subsequent modification (R-HSA-948021),9,+,6.53E-01,9.30E-01,7.85E-01,9.64E-01,,,,,,
GPCR downstream signalling (R-HSA-388396),9,-,8.00E-01,9.23E-01,7.83E-01,1.21E+00,,,,,,
Signaling by GPCR (R-HSA-372790),9,-,8.00E-01,9.21E-01,8.84E-01,9.95E-01,,,,,,
Diseases of signal transduction (R-HSA-5663202),9,+,9.06E-01,9.64E-01,8.83E-01,1.00E+00,,,,,,
Collagen chain trimerization (R-HSA-8948216),8,+,7.43E-02,1.25E+00,1.11E+00,9.51E-01,,,,,,
COPI-mediated anterograde transport (R-HSA-6807878),8,+,3.56E-01,7.09E-01,1.04E+00,9.92E-01,,,,,,
Infectious disease (R-HSA-5663205),8,+,4.85E-01,8.31E-01,8.93E-01,1.05E+00,,,,,,
M Phase (R-HSA-68886),8,-,5.04E-01,8.51E-01,6.66E-01,1.00E+00,,,,,,
Signaling by MET (R-HSA-6806834),8,+,6.14E-01,9.19E-01,8.67E-01,1.02E+00,,,,,,
Signaling by ROBO receptors (R-HSA-376176),8,+,8.63E-01,9.45E-01,8.73E-01,5.02E+00,,,,,,
MAPK family signaling cascades (R-HSA-5683057),8,-,9.05E-01,9.64E-01,9.85E-01,1.45E+00,,,,,,
NCAM signaling for neurite out-growth (R-HSA-375165),7,+,2.98E-02,1.54E+00,1.98E+00,1.10E+00,,,,,,
Metabolism of vitamins and cofactors (R-HSA-196854),7,+,1.32E-01,1.22E+00,1.23E+00,9.79E-01,,,,,,
tRNA Aminoacylation (R-HSA-379724),7,+,2.63E-01,9.16E-01,1.00E+00,1.01E+00,,,,,,
Transcriptional Regulation by TP53 (R-HSA-3700989),7,-,2.85E-01,9.14E-01,9.92E-01,1.13E+00,,,,,,
MET activates PTK2 signaling (R-HSA-8874081),7,+,3.07E-01,6.67E-01,8.86E-01,1.57E+00,,,,,,
MET promotes cell motility (R-HSA-8875878),7,+,3.07E-01,6.64E-01,8.68E-01,1.04E+00,,,,,,
Cell-Cell communication (R-HSA-1500931),7,-,4.92E-01,8.37E-01,6.69E-01,9.34E-01,,,,,,
Unfolded Protein Response (UPR) (R-HSA-381119),7,+,5.57E-01,8.84E-01,6.80E-01,1.04E+00,,,,,,
G alpha (i) signalling events (R-HSA-418594),7,-,6.40E-01,9.25E-01,7.83E-01,2.49E+00,,,,,,
Binding and Uptake of Ligands by Scavenger Receptors (R-HSA-2173782),7,-,7.24E-01,9.35E-01,8.83E-01,2.05E+00,,,,,,
Clathrin-mediated endocytosis (R-HSA-8856828),7,-,7.77E-01,9.29E-01,9.19E-01,1.00E+00,,,,,,
RAF/MAP kinase cascade (R-HSA-5673001),7,-,7.84E-01,9.31E-01,9.22E-01,1.64E+00,,,,,,
MAPK1/MAPK3 signaling (R-HSA-5684996),7,-,7.84E-01,9.29E-01,9.20E-01,1.13E+00,,,,,,
Class I MHC mediated antigen processing & presentation (R-HSA-983169),7,+,9.88E-01,1.00E+00,9.58E-01,1.02E+00,,,,,,
"Plasma lipoprotein assembly, remodeling, and clearance (R-HSA-174824)",6,-,1.02E-01,1.37E+00,1.35E+00,1.05E+00,,,,,,
trans-Golgi Network Vesicle Budding (R-HSA-199992),6,+,1.62E-01,1.05E+00,9.66E-01,9.86E-01,,,,,,
Golgi Associated Vesicle Biogenesis (R-HSA-432722),6,+,1.62E-01,1.04E+00,6.59E-01,9.98E-01,,,,,,
Clathrin derived vesicle budding (R-HSA-421837),6,+,1.62E-01,1.03E+00,7.45E-01,1.05E+00,,,,,,
Interferon Signaling (R-HSA-913531),6,+,1.98E-01,9.61E-01,7.53E-01,9.47E-01,,,,,,
The citric acid (TCA) cycle and respiratory electron transport (R-HSA-1428517),6,+,2.70E-01,9.15E-01,7.51E-01,1.05E+00,,,,,,
L1CAM interactions (R-HSA-373760),6,+,2.87E-01,9.17E-01,7.58E-01,1.00E+00,,,,,,
Fatty acid metabolism (R-HSA-8978868),6,+,4.08E-01,7.67E-01,7.77E-01,9.99E-01,,,,,,
Oncogenic MAPK signaling (R-HSA-6802957),6,+,5.43E-01,8.76E-01,7.75E-01,1.00E+00,,,,,,
Signaling by BRAF and RAF fusions (R-HSA-6802952),6,+,5.43E-01,8.74E-01,7.73E-01,9.84E-01,,,,,,
Cytosolic tRNA aminoacylation (R-HSA-379716),6,+,5.56E-01,8.83E-01,7.82E-01,1.08E+00,,,,,,
Syndecan interactions (R-HSA-3000170),6,+,6.28E-01,9.32E-01,8.36E-01,1.04E+00,,,,,,
Cell surface interactions at the vascular wall (R-HSA-202733),6,-,6.31E-01,9.27E-01,8.28E-01,9.98E-01,,,,,,
Caspase-mediated cleavage of cytoskeletal proteins (R-HSA-264870),6,+,6.35E-01,9.22E-01,9.27E-01,1.10E+00,,,,,,
Smooth Muscle Contraction (R-HSA-445355),6,-,7.39E-01,9.34E-01,9.41E-01,1.12E+00,,,,,,
RHO GTPases activate PAKs (R-HSA-5627123),6,-,9.58E-01,9.83E-01,9.39E-01,1.04E+00,,,,,,
Mitotic Metaphase and Anaphase (R-HSA-2555396),5,-,2.07E-02,4.63E+00,1.23E+00,1.02E+00,,,,,,
Mitotic Anaphase (R-HSA-68882),5,-,2.07E-02,3.47E+00,9.80E-01,1.00E+00,,,,,,
Cell Cycle Checkpoints (R-HSA-69620),5,-,2.31E-02,2.58E+00,9.69E-01,1.09E+00,,,,,,
Signaling by PDGF (R-HSA-186797),5,+,2.98E-02,1.43E+00,9.58E-01,2.48E+00,,,,,,
Formation of the cornified envelope (R-HSA-6809371),5,+,3.49E-02,1.06E+00,1.01E+00,1.10E+00,,,,,,
Keratinization (R-HSA-6805567),5,+,3.49E-02,1.02E+00,9.53E-01,1.04E+00,,,,,,
Selenoamino acid metabolism (R-HSA-2408522),5,+,1.45E-01,1.01E+00,9.46E-01,1.03E+00,,,,,,
Cargo recognition for clathrin-mediated endocytosis (R-HSA-8856825),5,-,2.65E-01,9.18E-01,9.05E-01,1.09E+00,,,,,,
Intra-Golgi and retrograde Golgi-to-ER traffic (R-HSA-6811442),5,-,3.20E-01,6.82E-01,8.73E-01,1.03E+00,,,,,,
Intracellular signaling by second messengers (R-HSA-9006925),5,-,3.54E-01,7.08E-01,7.03E-01,2.35E+00,,,,,,
Regulation of mRNA stability by proteins that bind AU-rich elements (R-HSA-450531),5,-,4.93E-01,8.37E-01,7.23E-01,1.00E+00,,,,,,
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807),5,-,5.26E-01,8.61E-01,7.46E-01,1.01E+00,,,,,,
Glucose metabolism (R-HSA-70326),5,+,6.07E-01,9.22E-01,7.71E-01,1.00E+00,,,,,,
Gluconeogenesis (R-HSA-70263),5,+,6.07E-01,9.20E-01,7.69E-01,9.85E-01,,,,,,
Regulation of expression of SLITs and ROBOs (R-HSA-9010553),5,-,6.44E-01,9.22E-01,7.80E-01,9.85E-01,,,,,,
Eukaryotic Translation Initiation (R-HSA-72613),5,-,7.40E-01,9.30E-01,8.60E-01,2.22E+00,,,,,,
Cap-dependent Translation Initiation (R-HSA-72737),5,-,7.40E-01,9.29E-01,9.29E-01,1.03E+00,,,,,,
GTP hydrolysis and joining of the 60S ribosomal subunit (R-HSA-72706),5,-,7.40E-01,9.27E-01,9.28E-01,1.00E+00,,,,,,
Antigen processing-Cross presentation (R-HSA-1236975),5,-,7.72E-01,9.30E-01,9.31E-01,9.60E-01,,,,,,
ER-Phagosome pathway (R-HSA-1236974),5,-,7.72E-01,9.29E-01,9.29E-01,9.80E-01,,,,,,
XBP1(S) activates chaperone genes (R-HSA-381038),5,+,7.92E-01,9.17E-01,9.43E-01,9.76E-01,,,,,,
IRE1alpha activates chaperones (R-HSA-381070),5,+,7.92E-01,9.15E-01,9.42E-01,3.08E+00,,,,,,
Scavenging by Class A Receptors (R-HSA-3000480),5,-,8.90E-01,9.65E-01,9.80E-01,1.01E+00,,,,,,
NCAM1 interactions (R-HSA-419037),4,+,2.27E-02,3.05E+00,2.32E+00,1.11E+00,,,,,,
Separation of Sister Chromatids (R-HSA-2467813),4,-,2.64E-02,1.48E+00,2.14E+00,9.67E-01,,,,,,
Signaling by the B Cell Receptor (BCR) (R-HSA-983705),4,-,3.20E-02,1.34E+00,1.99E+00,1.08E+00,,,,,,
G2/M Transition (R-HSA-69275),4,-,1.17E-01,1.34E+00,1.46E+00,1.03E+00,,,,,,
Mitotic G2-G2/M phases (R-HSA-453274),4,-,1.17E-01,1.31E+00,1.41E+00,1.00E+00,,,,,,
AUF1 (hnRNP D0) binds and destabilizes mRNA (R-HSA-450408),4,-,1.93E-01,9.44E-01,1.52E+00,1.03E+00,,,,,,
Mitotic Prophase (R-HSA-68875),4,+,2.05E-01,9.62E-01,1.19E+00,1.12E+00,,,,,,
Integration of energy metabolism (R-HSA-163685),4,-,2.24E-01,1.01E+00,9.82E-01,1.24E+00,,,,,,
Metabolism of polyamines (R-HSA-351202),4,-,2.24E-01,1.00E+00,9.67E-01,2.91E+00,,,,,,
Neuronal System (R-HSA-112316),4,-,2.57E-01,1.00E+00,1.02E+00,9.48E-01,,,,,,
Protein-protein interactions at synapses (R-HSA-6794362),4,-,2.57E-01,9.97E-01,9.76E-01,2.73E+00,,,,,,
Neurexins and neuroligins (R-HSA-6794361),4,-,2.57E-01,9.91E-01,9.35E-01,1.06E+00,,,,,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933),4,+,2.60E-01,9.84E-01,9.14E-01,9.98E-01,,,,,,
Glycosaminoglycan metabolism (R-HSA-1630316),4,+,3.62E-01,7.15E-01,9.08E-01,9.97E-01,,,,,,
Transcriptional regulation by RUNX1 (R-HSA-8878171),4,-,3.75E-01,7.28E-01,9.03E-01,1.77E+00,,,,,,
N-glycan trimming in the ER and Calnexin/Calreticulin cycle (R-HSA-532668),4,+,4.34E-01,8.00E-01,9.06E-01,9.62E-01,,,,,,
Calnexin/calreticulin cycle (R-HSA-901042),4,+,4.34E-01,7.97E-01,8.94E-01,1.09E+00,,,,,,
Visual phototransduction (R-HSA-2187338),4,+,4.72E-01,8.28E-01,8.98E-01,9.79E-01,,,,,,
Metabolism of fat-soluble vitamins (R-HSA-6806667),4,+,4.72E-01,8.26E-01,6.47E-01,1.22E+00,,,,,,
Retinoid metabolism and transport (R-HSA-975634),4,+,4.72E-01,8.23E-01,7.14E-01,1.09E+00,,,,,,
HIV Infection (R-HSA-162906),4,+,4.83E-01,8.29E-01,7.42E-01,1.06E+00,,,,,,
Rho GTPase cycle (R-HSA-194840),4,+,5.05E-01,8.52E-01,7.50E-01,1.10E+00,,,,,,
Signaling by Hedgehog (R-HSA-5358351),4,-,5.51E-01,8.85E-01,7.78E-01,1.00E+00,,,,,,
L13a-mediated translational silencing of Ceruloplasmin expression (R-HSA-156827),4,-,5.55E-01,8.85E-01,7.82E-01,1.23E+00,,,,,,
Platelet Aggregation (Plug Formation) (R-HSA-76009),4,-,5.75E-01,9.06E-01,7.80E-01,2.66E+00,,,,,,
Cell junction organization (R-HSA-446728),4,-,5.91E-01,9.12E-01,7.78E-01,1.00E+00,,,,,,
Mitochondrial Fatty Acid Beta-Oxidation (R-HSA-77289),4,+,5.99E-01,9.18E-01,8.17E-01,1.01E+00,,,,,,
Transcriptional regulation by RUNX2 (R-HSA-8878166),4,-,6.36E-01,9.22E-01,8.28E-01,1.03E+00,,,,,,
Antigen processing: Ubiquitination & Proteasome degradation (R-HSA-983168),4,-,7.04E-01,9.41E-01,8.56E-01,9.98E-01,,,,,,
Pyruvate metabolism and Citric Acid (TCA) cycle (R-HSA-71406),4,+,7.79E-01,9.29E-01,9.04E-01,1.02E+00,,,,,,
Interleukin-12 family signaling (R-HSA-447115),4,+,8.02E-01,9.21E-01,9.10E-01,1.21E+00,,,,,,
Striated Muscle Contraction (R-HSA-390522),4,+,8.70E-01,9.46E-01,9.25E-01,9.96E-01,,,,,,
Semaphorin interactions (R-HSA-373755),4,-,8.93E-01,9.59E-01,9.32E-01,9.97E-01,,,,,,
RHO GTPases Activate Formins (R-HSA-5663220),4,-,9.49E-01,9.79E-01,9.42E-01,9.97E-01,,,,,,
Deubiquitination (R-HSA-5688426),4,+,9.72E-01,9.91E-01,9.49E-01,1.04E+00,,,,,,
Interferon gamma signaling (R-HSA-877300),3,+,1.96E-02,6.57E+00,4.51E+00,1.01E+00,,,,,,
Plasma lipoprotein clearance (R-HSA-8964043),3,-,3.42E-02,1.09E+00,3.74E+00,9.91E-01,,,,,,
Regulation of actin dynamics for phagocytic cup formation (R-HSA-2029482),3,+,4.03E-02,1.04E+00,3.11E+00,2.13E+00,,,,,,
Fcgamma receptor (FCGR) dependent phagocytosis (R-HSA-2029480),3,+,4.03E-02,1.00E+00,1.48E+00,2.03E+00,,,,,,
Amyloid fiber formation (R-HSA-977225),3,+,6.96E-02,1.34E+00,1.40E+00,1.01E+00,,,,,,
Deadenylation of mRNA (R-HSA-429947),3,-,7.95E-02,1.30E+00,1.40E+00,9.87E-01,,,,,,
Deadenylation-dependent mRNA decay (R-HSA-429914),3,-,7.95E-02,1.27E+00,1.44E+00,1.00E+00,,,,,,
Organelle biogenesis and maintenance (R-HSA-1852241),3,-,1.09E-01,1.40E+00,1.54E+00,9.94E-01,,,,,,
MHC class II antigen presentation (R-HSA-2132295),3,-,1.10E-01,1.37E+00,1.50E+00,1.00E+00,,,,,,
Disorders of transmembrane transporters (R-HSA-5619115),3,-,1.38E-01,1.14E+00,1.10E+00,9.91E-01,,,,,,
Metabolism of water-soluble vitamins and cofactors (R-HSA-196849),3,+,1.38E-01,1.13E+00,1.04E+00,1.01E+00,,,,,,
Neurodegenerative Diseases (R-HSA-8863678),3,-,1.61E-01,1.06E+00,9.93E-01,1.05E+00,,,,,,
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models (R-HSA-8862803),3,-,1.61E-01,1.05E+00,9.83E-01,2.70E+00,,,,,,
Beta oxidation of palmitoyl-CoA to myristoyl-CoA (R-HSA-77305),3,+,1.63E-01,1.02E+00,9.66E-01,9.98E-01,,,,,,
mitochondrial fatty acid beta-oxidation of saturated fatty acids (R-HSA-77286),3,+,1.63E-01,1.01E+00,9.78E-01,1.02E+00,,,,,,
Apoptotic cleavage of cell adhesion  proteins (R-HSA-351906),3,-,2.00E-01,9.47E-01,1.01E+00,1.03E+00,,,,,,
Mitotic Prometaphase (R-HSA-68877),3,-,2.15E-01,9.88E-01,1.02E+00,1.10E+00,,,,,,
G2/M Checkpoints (R-HSA-69481),3,-,2.25E-01,1.00E+00,9.93E-01,1.00E+00,,,,,,
Major pathway of rRNA processing in the nucleolus and cytosol (R-HSA-6791226),3,+,2.75E-01,9.28E-01,9.85E-01,1.00E+00,,,,,,
rRNA processing (R-HSA-72312),3,+,2.75E-01,9.23E-01,9.77E-01,9.95E-01,,,,,,
rRNA processing in the nucleus and cytosol (R-HSA-8868773),3,+,2.75E-01,9.19E-01,9.25E-01,9.61E-01,,,,,,
Influenza Life Cycle (R-HSA-168255),3,+,2.81E-01,9.29E-01,9.38E-01,9.88E-01,,,,,,
Influenza Infection (R-HSA-168254),3,+,2.81E-01,9.25E-01,9.51E-01,1.05E+00,,,,,,
Platelet homeostasis (R-HSA-418346),3,-,3.09E-01,6.65E-01,9.06E-01,1.01E+00,,,,,,
Hedgehog 'off' state (R-HSA-5610787),3,-,3.22E-01,6.67E-01,8.99E-01,1.00E+00,,,,,,
Toll-Like Receptors Cascades (R-HSA-168898),3,-,3.29E-01,6.77E-01,8.94E-01,9.93E-01,,,,,,
Cell-extracellular matrix interactions (R-HSA-446353),3,-,3.46E-01,6.95E-01,8.89E-01,1.01E+00,,,,,,
Neddylation (R-HSA-8951664),3,-,3.96E-01,7.58E-01,8.74E-01,9.99E-01,,,,,,
"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. (R-HSA-163200)",3,+,4.43E-01,8.04E-01,8.70E-01,9.98E-01,,,,,,
Respiratory electron transport (R-HSA-611105),3,+,4.43E-01,8.01E-01,8.71E-01,1.01E+00,,,,,,
SeMet incorporation into proteins (R-HSA-2408517),3,+,4.51E-01,8.12E-01,8.64E-01,9.88E-01,,,,,,
UCH proteinases (R-HSA-5689603),3,-,4.59E-01,8.07E-01,8.69E-01,1.07E+00,,,,,,
SUMO E3 ligases SUMOylate target proteins (R-HSA-3108232),3,-,4.76E-01,8.27E-01,8.65E-01,1.07E+00,,,,,,
SUMOylation (R-HSA-2990846),3,-,4.76E-01,8.25E-01,6.52E-01,1.09E+00,,,,,,
Interaction between L1 and Ankyrins (R-HSA-445095),3,+,4.80E-01,8.26E-01,6.50E-01,1.04E+00,,,,,,
Laminin interactions (R-HSA-3000157),3,+,5.06E-01,8.50E-01,6.58E-01,9.91E-01,,,,,,
Regulation of RUNX2 expression and activity (R-HSA-8939902),3,-,5.10E-01,8.56E-01,6.56E-01,9.70E-01,,,,,,
Signaling by NOTCH (R-HSA-157118),3,-,5.10E-01,8.53E-01,6.66E-01,1.09E+00,,,,,,
SRP-dependent cotranslational protein targeting to membrane (R-HSA-1799339),3,+,5.32E-01,8.64E-01,7.14E-01,1.09E+00,,,,,,
MAPK6/MAPK4 signaling (R-HSA-5687128),3,-,5.41E-01,8.75E-01,7.03E-01,1.09E+00,,,,,,
TP53 Regulates Metabolic Genes (R-HSA-5628897),3,-,5.54E-01,8.86E-01,7.01E-01,9.84E-01,,,,,,
GP1b-IX-V activation signalling (R-HSA-430116),3,-,5.86E-01,9.11E-01,7.00E-01,1.05E+00,,,,,,
Hedgehog ligand biogenesis (R-HSA-5358346),3,-,5.91E-01,9.10E-01,7.16E-01,1.80E+00,,,,,,
Antiviral mechanism by IFN-stimulated genes (R-HSA-1169410),3,-,6.15E-01,9.19E-01,7.14E-01,1.01E+00,,,,,,
ISG15 antiviral mechanism (R-HSA-1169408),3,-,6.15E-01,9.17E-01,7.73E-01,1.03E+00,,,,,,
RHO GTPases activate CIT (R-HSA-5625900),3,-,6.34E-01,9.29E-01,7.81E-01,9.80E-01,,,,,,
RHO GTPases Activate ROCKs (R-HSA-5627117),3,-,6.34E-01,9.27E-01,7.88E-01,1.13E+00,,,,,,
RHO GTPases activate PKNs (R-HSA-5625740),3,-,6.34E-01,9.25E-01,7.86E-01,1.12E+00,,,,,,
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC (R-HSA-983170)",3,+,6.43E-01,9.23E-01,7.80E-01,1.02E+00,,,,,,
Nephrin family interactions (R-HSA-373753),3,-,6.63E-01,9.21E-01,8.35E-01,1.11E+00,,,,,,
DNA Repair (R-HSA-73894),3,-,6.68E-01,9.18E-01,8.33E-01,1.10E+00,,,,,,
Nonhomologous End-Joining (NHEJ) (R-HSA-5693571),3,-,6.68E-01,9.16E-01,8.34E-01,9.91E-01,,,,,,
DNA Double-Strand Break Repair (R-HSA-5693532),3,-,6.68E-01,9.15E-01,8.32E-01,9.99E-01,,,,,,
COPII-mediated vesicle transport (R-HSA-204005),3,+,7.03E-01,9.47E-01,8.31E-01,1.58E+00,,,,,,
p75 NTR receptor-mediated signalling (R-HSA-193704),3,-,7.08E-01,9.44E-01,8.26E-01,1.10E+00,,,,,,
Death Receptor Signalling (R-HSA-73887),3,-,7.08E-01,9.42E-01,8.31E-01,1.05E+00,,,,,,
Detoxification of Reactive Oxygen Species (R-HSA-3299685),3,-,7.74E-01,9.29E-01,8.29E-01,1.02E+00,,,,,,
Biological oxidations (R-HSA-211859),3,+,7.79E-01,9.30E-01,8.85E-01,1.01E+00,,,,,,
PIP3 activates AKT signaling (R-HSA-1257604),3,-,8.05E-01,9.20E-01,8.70E-01,9.83E-01,,,,,,
PTEN Regulation (R-HSA-6807070),3,-,8.05E-01,9.19E-01,8.62E-01,1.10E+00,,,,,,
Nonsense-Mediated Decay (NMD) (R-HSA-927802),3,+,8.10E-01,9.19E-01,8.60E-01,1.05E+00,,,,,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) (R-HSA-975957),3,+,8.10E-01,9.17E-01,8.59E-01,1.01E+00,,,,,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) (R-HSA-975956),3,+,8.10E-01,9.15E-01,8.63E-01,9.75E-01,,,,,,
Signaling by EGFR (R-HSA-177929),3,-,8.69E-01,9.49E-01,9.10E-01,9.20E-01,,,,,,
Diseases of glycosylation (R-HSA-3781865),3,+,8.69E-01,9.48E-01,9.22E-01,9.87E-01,,,,,,
Diseases associated with glycosaminoglycan metabolism (R-HSA-3560782),3,+,8.69E-01,9.46E-01,9.27E-01,9.35E-01,,,,,,
Plasma lipoprotein assembly (R-HSA-8963898),3,-,8.95E-01,9.60E-01,9.30E-01,9.37E-01,,,,,,
ABC-family proteins mediated transport (R-HSA-382556),3,-,9.01E-01,9.64E-01,9.31E-01,9.84E-01,,,,,,
Interleukin-12 signaling (R-HSA-9020591),3,+,9.11E-01,9.64E-01,9.57E-01,9.81E-01,,,,,,
Glycolysis (R-HSA-70171),3,+,9.17E-01,9.69E-01,9.58E-01,9.71E-01,,,,,,
Signaling by WNT (R-HSA-195721),3,-,9.22E-01,9.67E-01,9.57E-01,9.50E-01,,,,,,
Beta-catenin independent WNT signaling (R-HSA-3858494),3,-,9.22E-01,9.65E-01,9.55E-01,9.43E-01,,,,,,
PCP/CE pathway (R-HSA-4086400),3,-,9.22E-01,9.64E-01,9.74E-01,1.01E+00,,,,,,
Metabolism of steroids (R-HSA-8957322),3,-,9.38E-01,9.77E-01,9.86E-01,1.04E+00,,,,,,
Host Interactions of HIV factors (R-HSA-162909),3,+,9.87E-01,1.00E+00,9.85E-01,9.98E-01,,,,,,
Citric acid cycle (TCA cycle) (R-HSA-71403),3,-,9.97E-01,9.99E-01,9.83E-01,1.77E+00,,,,,,
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S (R-HSA-72662)",2,-,2.58E-02,2.47E+00,7.93E+00,1.13E+00,,,,,,
Translation initiation complex formation (R-HSA-72649),2,-,2.58E-02,2.16E+00,5.29E+00,9.96E-01,,,,,,
mTOR signalling (R-HSA-165159),2,-,2.58E-02,1.92E+00,3.52E+00,2.04E+00,,,,,,
Ribosomal scanning and start codon recognition (R-HSA-72702),2,-,2.58E-02,1.73E+00,3.08E+00,1.13E+00,,,,,,
mTORC1-mediated signalling (R-HSA-166208),2,-,2.58E-02,1.57E+00,2.74E+00,1.13E+00,,,,,,
Signaling by Hippo (R-HSA-2028269),2,-,3.18E-02,1.42E+00,2.46E+00,1.10E+00,,,,,,
Resolution of Sister Chromatid Cohesion (R-HSA-2500257),2,-,3.38E-02,1.34E+00,2.24E+00,9.92E-01,,,,,,
Mitotic Spindle Checkpoint (R-HSA-69618),2,-,3.38E-02,1.26E+00,1.97E+00,9.88E-01,,,,,,
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal (R-HSA-141444),2,-,3.38E-02,1.19E+00,1.84E+00,1.10E+00,,,,,,
Amplification of signal from the kinetochores (R-HSA-141424),2,-,3.38E-02,1.14E+00,1.74E+00,1.13E+00,,,,,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain (R-HSA-6803205),2,-,3.60E-02,1.01E+00,1.64E+00,1.02E+00,,,,,,
TP53 Regulates Transcription of Cell Death Genes (R-HSA-5633008),2,-,3.60E-02,9.66E-01,1.55E+00,1.13E+00,,,,,,
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers (R-HSA-983695),2,-,4.40E-02,1.05E+00,1.48E+00,1.12E+00,,,,,,
LDL clearance (R-HSA-8964038),2,-,5.66E-02,1.27E+00,1.41E+00,1.12E+00,,,,,,
Diseases of metabolism (R-HSA-5668914),2,-,7.34E-02,1.37E+00,1.34E+00,1.12E+00,,,,,,
Glycogen storage diseases (R-HSA-3229121),2,-,7.34E-02,1.33E+00,1.28E+00,1.12E+00,,,,,,
Diseases of carbohydrate metabolism (R-HSA-5663084),2,-,7.34E-02,1.30E+00,1.42E+00,1.12E+00,,,,,,
Glycogen metabolism (R-HSA-8982491),2,-,7.34E-02,1.26E+00,1.45E+00,1.17E+00,,,,,,
Golgi Cisternae Pericentriolar Stack Reorganization (R-HSA-162658),2,+,8.47E-02,1.32E+00,1.05E+00,1.13E+00,,,,,,
G alpha (q) signalling events (R-HSA-416476),2,-,1.10E-01,1.39E+00,1.03E+00,1.11E+00,,,,,,
Plasma lipoprotein remodeling (R-HSA-8963899),2,-,1.36E-01,1.23E+00,1.02E+00,9.73E-01,,,,,,
Glycerophospholipid biosynthesis (R-HSA-1483206),2,+,1.42E-01,1.12E+00,1.03E+00,1.11E+00,,,,,,
Acyl chain remodeling of CL (R-HSA-1482798),2,+,1.42E-01,1.11E+00,9.69E-01,4.32E+00,,,,,,
Beta oxidation of hexanoyl-CoA to butanoyl-CoA (R-HSA-77350),2,+,1.42E-01,1.10E+00,9.95E-01,1.03E+00,,,,,,
Beta oxidation of octanoyl-CoA to hexanoyl-CoA (R-HSA-77348),2,+,1.42E-01,1.09E+00,9.84E-01,9.67E-01,,,,,,
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA (R-HSA-77346),2,+,1.42E-01,1.07E+00,9.74E-01,1.96E+00,,,,,,
Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA (R-HSA-77310),2,+,1.42E-01,1.06E+00,1.04E+00,1.01E+00,,,,,,
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids (R-HSA-77288),2,+,1.42E-01,1.05E+00,1.01E+00,1.01E+00,,,,,,
Beta oxidation of myristoyl-CoA to lauroyl-CoA (R-HSA-77285),2,+,1.42E-01,1.04E+00,1.03E+00,1.16E+00,,,,,,
Phospholipid metabolism (R-HSA-1483257),2,+,1.42E-01,1.03E+00,1.02E+00,2.92E+00,,,,,,
Peptide chain elongation (R-HSA-156902),2,+,1.64E-01,1.01E+00,1.01E+00,1.11E+00,,,,,,
Formation of a pool of free 40S subunits (R-HSA-72689),2,+,1.64E-01,9.99E-01,1.00E+00,9.84E-01,,,,,,
Eukaryotic Translation Elongation (R-HSA-156842),2,+,1.64E-01,9.90E-01,9.46E-01,1.01E+00,,,,,,
Eukaryotic Translation Termination (R-HSA-72764),2,+,1.64E-01,9.81E-01,9.50E-01,9.83E-01,,,,,,
Viral mRNA Translation (R-HSA-192823),2,+,1.64E-01,9.72E-01,9.00E-01,1.11E+00,,,,,,
Selenocysteine synthesis (R-HSA-2408557),2,+,1.64E-01,9.64E-01,9.07E-01,1.11E+00,,,,,,
Influenza Viral RNA Transcription and Replication (R-HSA-168273),2,+,1.64E-01,9.55E-01,8.69E-01,1.10E+00,,,,,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane (R-HSA-1445148),2,+,1.69E-01,9.36E-01,8.65E-01,1.10E+00,,,,,,
SLC-mediated transmembrane transport (R-HSA-425407),2,-,1.82E-01,9.18E-01,8.61E-01,1.10E+00,,,,,,
Gap junction trafficking and regulation (R-HSA-157858),2,-,1.87E-01,9.32E-01,8.57E-01,9.87E-01,,,,,,
Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942),2,-,2.33E-01,1.01E+00,8.53E-01,1.10E+00,,,,,,
Opioid Signalling (R-HSA-111885),2,-,2.42E-01,1.05E+00,8.50E-01,1.10E+00,,,,,,
CaM pathway (R-HSA-111997),2,-,2.42E-01,1.04E+00,8.46E-01,9.79E-01,,,,,,
Ca-dependent events (R-HSA-111996),2,-,2.42E-01,1.04E+00,8.42E-01,1.09E+00,,,,,,
DAG and IP3 signaling (R-HSA-1489509),2,-,2.42E-01,1.03E+00,8.39E-01,1.09E+00,,,,,,
Calmodulin induced events (R-HSA-111933),2,-,2.42E-01,1.02E+00,8.35E-01,1.86E+00,,,,,,
PLC beta mediated events (R-HSA-112043),2,-,2.42E-01,1.02E+00,8.31E-01,1.10E+00,,,,,,
G-protein mediated events (R-HSA-112040),2,-,2.42E-01,1.01E+00,8.28E-01,1.10E+00,,,,,,
Miscellaneous transport and binding events (R-HSA-5223345),2,-,2.53E-01,1.00E+00,8.24E-01,1.14E+00,,,,,,
Pentose phosphate pathway (R-HSA-71336),2,-,2.78E-01,9.22E-01,8.21E-01,9.67E-01,,,,,,
Signaling by Nuclear Receptors (R-HSA-9006931),2,+,2.81E-01,9.20E-01,8.17E-01,1.09E+00,,,,,,
Sulfur amino acid metabolism (R-HSA-1614635),2,+,3.00E-01,9.20E-01,8.14E-01,1.11E+00,,,,,,
The role of GTSE1 in G2/M progression after G2 checkpoint (R-HSA-8852276),2,-,3.04E-01,9.27E-01,8.10E-01,1.09E+00,,,,,,
Ub-specific processing proteases (R-HSA-5689880),2,-,3.04E-01,9.23E-01,8.07E-01,1.13E+00,,,,,,
Ubiquitin-dependent degradation of Cyclin D (R-HSA-75815),2,-,3.04E-01,9.19E-01,8.03E-01,1.12E+00,,,,,,
Defective CFTR causes cystic fibrosis (R-HSA-5678895),2,-,3.04E-01,9.15E-01,8.00E-01,1.02E+00,,,,,,
CDK-mediated phosphorylation and removal of Cdc6 (R-HSA-69017),2,-,3.04E-01,9.11E-01,7.97E-01,1.03E+00,,,,,,
APC/C:Cdc20 mediated degradation of mitotic proteins (R-HSA-176409),2,-,3.04E-01,9.07E-01,7.93E-01,1.09E+00,,,,,,
Regulation of APC/C activators between G1/S and early anaphase (R-HSA-176408),2,-,3.04E-01,9.03E-01,7.90E-01,1.08E+00,,,,,,
DNA Replication Pre-Initiation (R-HSA-69002),2,-,3.04E-01,8.99E-01,7.87E-01,1.08E+00,,,,,,
Vif-mediated degradation of APOBEC3G (R-HSA-180585),2,-,3.04E-01,8.95E-01,7.84E-01,1.08E+00,,,,,,
Cellular response to hypoxia (R-HSA-2262749),2,-,3.04E-01,8.91E-01,7.80E-01,9.94E-01,,,,,,
Regulation of activated PAK-2p34 by proteasome mediated degradation (R-HSA-211733),2,-,3.04E-01,8.87E-01,7.77E-01,1.08E+00,,,,,,
Vpu mediated degradation of CD4 (R-HSA-180534),2,-,3.04E-01,8.83E-01,7.74E-01,1.08E+00,,,,,,
DNA Replication (R-HSA-69306),2,-,3.04E-01,8.79E-01,7.71E-01,9.75E-01,,,,,,
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha (R-HSA-1234176),2,-,3.04E-01,8.75E-01,7.68E-01,9.81E-01,,,,,,
Regulation of Hypoxia-inducible Factor (HIF) by oxygen (R-HSA-1234174),2,-,3.04E-01,8.72E-01,7.65E-01,9.80E-01,,,,,,
Regulation of PTEN stability and activity (R-HSA-8948751),2,-,3.04E-01,8.68E-01,7.62E-01,9.75E-01,,,,,,
Cyclin A:Cdk2-associated events at S phase entry (R-HSA-69656),2,-,3.04E-01,8.64E-01,7.59E-01,1.07E+00,,,,,,
Autodegradation of Cdh1 by Cdh1:APC/C (R-HSA-174084),2,-,3.04E-01,8.61E-01,7.56E-01,2.63E+00,,,,,,
Regulation of ornithine decarboxylase (ODC) (R-HSA-350562),2,-,3.04E-01,8.57E-01,7.53E-01,1.07E+00,,,,,,
Downstream TCR signaling (R-HSA-202424),2,-,3.04E-01,8.53E-01,7.50E-01,1.07E+00,,,,,,
SCF(Skp2)-mediated degradation of p27/p21 (R-HSA-187577),2,-,3.04E-01,8.50E-01,7.47E-01,1.07E+00,,,,,,
TCF dependent signaling in response to WNT (R-HSA-201681),2,-,3.04E-01,8.46E-01,7.44E-01,9.71E-01,,,,,,
TCR signaling (R-HSA-202403),2,-,3.04E-01,8.43E-01,7.41E-01,9.67E-01,,,,,,
G1/S DNA Damage Checkpoints (R-HSA-69615),2,-,3.04E-01,8.39E-01,7.38E-01,9.63E-01,,,,,,
p53-Independent G1/S DNA damage checkpoint (R-HSA-69613),2,-,3.04E-01,8.36E-01,7.35E-01,1.07E+00,,,,,,
p53-Independent DNA Damage Response (R-HSA-69610),2,-,3.04E-01,8.33E-01,7.32E-01,1.11E+00,,,,,,
Downstream signaling events of B Cell Receptor (BCR) (R-HSA-1168372),2,-,3.04E-01,8.29E-01,7.30E-01,9.79E-01,,,,,,
Fc epsilon receptor (FCERI) signaling (R-HSA-2454202),2,-,3.04E-01,8.26E-01,7.27E-01,1.07E+00,,,,,,
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A (R-HSA-69601),2,-,3.04E-01,8.23E-01,7.24E-01,1.10E+00,,,,,,
M/G1 Transition (R-HSA-68874),2,-,3.04E-01,8.19E-01,7.21E-01,1.02E+00,,,,,,
Regulation of Apoptosis (R-HSA-169911),2,-,3.04E-01,8.16E-01,7.19E-01,9.83E-01,,,,,,
Hedgehog 'on' state (R-HSA-5632684),2,-,3.04E-01,8.13E-01,7.16E-01,1.03E+00,,,,,,
Degradation of beta-catenin by the destruction complex (R-HSA-195253),2,-,3.04E-01,8.09E-01,7.13E-01,9.61E-01,,,,,,
Assembly of the pre-replicative complex (R-HSA-68867),2,-,3.04E-01,8.06E-01,7.11E-01,1.06E+00,,,,,,
Cross-presentation of soluble exogenous antigens (endosomes) (R-HSA-1236978),2,-,3.04E-01,8.03E-01,7.08E-01,1.06E+00,,,,,,
Negative regulation of NOTCH4 signaling (R-HSA-9604323),2,-,3.04E-01,8.00E-01,7.05E-01,1.06E+00,,,,,,
CDT1 association with the CDC6:ORC:origin complex (R-HSA-68827),2,-,3.04E-01,7.97E-01,7.03E-01,1.10E+00,,,,,,
Regulation of RUNX3 expression and activity (R-HSA-8941858),2,-,3.04E-01,7.94E-01,7.00E-01,1.03E+00,,,,,,
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis (R-HSA-8854050),2,-,3.04E-01,7.91E-01,6.98E-01,9.70E-01,,,,,,
ABC transporter disorders (R-HSA-5619084),2,-,3.04E-01,7.88E-01,6.95E-01,1.01E+00,,,,,,
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins (R-HSA-176814),2,-,3.04E-01,7.85E-01,6.93E-01,1.01E+00,,,,,,
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD (R-HSA-5362768),2,-,3.04E-01,7.82E-01,6.90E-01,1.00E+00,,,,,,
Cdc20:Phospho-APC/C mediated degradation of Cyclin A (R-HSA-174184),2,-,3.04E-01,7.79E-01,6.88E-01,1.06E+00,,,,,,
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 (R-HSA-174178),2,-,3.04E-01,7.76E-01,6.85E-01,9.79E-01,,,,,,
RUNX1 regulates transcription of genes involved in differentiation of HSCs (R-HSA-8939236),2,-,3.04E-01,7.73E-01,6.83E-01,1.00E+00,,,,,,
CLEC7A (Dectin-1) signaling (R-HSA-5607764),2,-,3.04E-01,7.70E-01,6.80E-01,1.02E+00,,,,,,
Dectin-1 mediated noncanonical NF-kB signaling (R-HSA-5607761),2,-,3.04E-01,7.67E-01,6.78E-01,1.10E+00,,,,,,
C-type lectin receptors (CLRs) (R-HSA-5621481),2,-,3.04E-01,7.64E-01,6.76E-01,1.06E+00,,,,,,
Signaling by NOTCH4 (R-HSA-9013694),2,-,3.04E-01,7.61E-01,6.73E-01,1.06E+00,,,,,,
APC/C:Cdc20 mediated degradation of Securin (R-HSA-174154),2,-,3.04E-01,7.58E-01,6.71E-01,1.10E+00,,,,,,
TNFR2 non-canonical NF-kB pathway (R-HSA-5668541),2,-,3.04E-01,7.56E-01,6.68E-01,1.05E+00,,,,,,
APC/C-mediated degradation of cell cycle proteins (R-HSA-174143),2,-,3.04E-01,7.53E-01,6.66E-01,9.78E-01,,,,,,
Hh mutants abrogate ligand secretion (R-HSA-5387390),2,-,3.04E-01,7.50E-01,6.64E-01,9.99E-01,,,,,,
Asymmetric localization of PCP proteins (R-HSA-4608870),2,-,3.04E-01,7.47E-01,6.62E-01,1.10E+00,,,,,,
Activation of NF-kappaB in B cells (R-HSA-1169091),2,-,3.04E-01,7.44E-01,6.59E-01,1.05E+00,,,,,,
SCF-beta-TrCP mediated degradation of Emi1 (R-HSA-174113),2,-,3.04E-01,7.42E-01,6.57E-01,1.05E+00,,,,,,
S Phase (R-HSA-69242),2,-,3.04E-01,7.39E-01,6.55E-01,1.05E+00,,,,,,
NIK-->noncanonical NF-kB signaling (R-HSA-5676590),2,-,3.04E-01,7.36E-01,6.52E-01,1.04E+00,,,,,,
Synthesis of DNA (R-HSA-69239),2,-,3.04E-01,7.34E-01,6.50E-01,1.89E+00,,,,,,
Orc1 removal from chromatin (R-HSA-68949),2,-,3.04E-01,7.31E-01,6.48E-01,1.05E+00,,,,,,
Ubiquitin-dependent degradation of Cyclin D1 (R-HSA-69229),2,-,3.04E-01,7.29E-01,6.46E-01,1.04E+00,,,,,,
FCERI mediated NF-kB activation (R-HSA-2871837),2,-,3.04E-01,7.26E-01,6.44E-01,1.04E+00,,,,,,
Interleukin-1 signaling (R-HSA-9020702),2,-,3.04E-01,7.23E-01,6.42E-01,1.04E+00,,,,,,
p53-Dependent G1/S DNA damage checkpoint (R-HSA-69580),2,-,3.04E-01,7.21E-01,6.39E-01,1.01E+00,,,,,,
Degradation of DVL (R-HSA-4641258),2,-,3.04E-01,7.18E-01,6.37E-01,1.01E+00,,,,,,
Degradation of AXIN (R-HSA-4641257),2,-,3.04E-01,7.16E-01,6.35E-01,1.04E+00,,,,,,
GLI3 is processed to GLI3R by the proteasome (R-HSA-5610785),2,-,3.04E-01,7.13E-01,6.75E-01,1.89E+00,,,,,,
Degradation of GLI2 by the proteasome (R-HSA-5610783),2,-,3.04E-01,7.11E-01,6.73E-01,1.04E+00,,,,,,
Degradation of GLI1 by the proteasome (R-HSA-5610780),2,-,3.04E-01,7.08E-01,6.71E-01,1.00E+00,,,,,,
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint (R-HSA-179419),2,-,3.04E-01,7.06E-01,6.69E-01,1.04E+00,,,,,,
G1/S Transition (R-HSA-69206),2,-,3.04E-01,7.03E-01,6.66E-01,1.03E+00,,,,,,
Cyclin E associated events during G1/S transition  (R-HSA-69202),2,-,3.04E-01,7.01E-01,6.64E-01,9.55E-01,,,,,,
p53-Dependent G1 DNA Damage Response (R-HSA-69563),2,-,3.04E-01,6.99E-01,6.62E-01,1.05E+00,,,,,,
Stabilization of p53 (R-HSA-69541),2,-,3.04E-01,6.96E-01,6.60E-01,9.75E-01,,,,,,
Interleukin-1 family signaling (R-HSA-446652),2,-,3.04E-01,6.94E-01,6.58E-01,1.03E+00,,,,,,
Autodegradation of the E3 ubiquitin ligase COP1 (R-HSA-349425),2,-,3.04E-01,6.91E-01,6.56E-01,1.03E+00,,,,,,
Regulation of RAS by GAPs (R-HSA-5658442),2,-,3.04E-01,6.89E-01,6.67E-01,1.03E+00,,,,,,
Mitotic G1-G1/S phases (R-HSA-453279),2,-,3.04E-01,6.87E-01,6.71E-01,1.03E+00,,,,,,
Regulation of mitotic cell cycle (R-HSA-453276),2,-,3.04E-01,6.85E-01,7.03E-01,1.03E+00,,,,,,
Transcriptional regulation by RUNX3 (R-HSA-8878159),2,-,3.04E-01,6.82E-01,7.01E-01,9.96E-01,,,,,,
Switching of origins to a post-replicative state (R-HSA-69052),2,-,3.04E-01,6.80E-01,6.99E-01,1.00E+00,,,,,,
Regulation of insulin secretion (R-HSA-422356),2,-,3.20E-01,6.84E-01,6.97E-01,1.02E+00,,,,,,
Cellular Senescence (R-HSA-2559583),2,-,3.36E-01,6.86E-01,6.95E-01,1.01E+00,,,,,,
Molecules associated with elastic fibres (R-HSA-2129379),2,+,3.45E-01,6.97E-01,6.93E-01,9.65E-01,,,,,,
Elastic fibre formation (R-HSA-1566948),2,+,3.45E-01,6.95E-01,7.56E-01,1.02E+00,,,,,,
Recycling pathway of L1 (R-HSA-437239),2,+,3.66E-01,7.21E-01,7.69E-01,9.70E-01,,,,,,
Golgi-to-ER retrograde transport (R-HSA-8856688),2,-,3.71E-01,7.23E-01,7.67E-01,1.01E+00,,,,,,
Mitochondrial biogenesis (R-HSA-1592230),2,-,3.80E-01,7.36E-01,7.85E-01,1.01E+00,,,,,,
Transcriptional regulation of white adipocyte differentiation (R-HSA-381340),2,-,4.12E-01,7.70E-01,7.77E-01,1.05E+00,,,,,,
Scavenging by Class F Receptors (R-HSA-3000484),2,-,4.41E-01,8.06E-01,7.81E-01,1.03E+00,,,,,,
Phase II - Conjugation of compounds (R-HSA-156580),2,-,4.91E-01,8.39E-01,7.81E-01,1.02E+00,,,,,,
Netrin-1 signaling (R-HSA-373752),2,-,5.23E-01,8.58E-01,8.31E-01,1.05E+00,,,,,,
Ion homeostasis (R-HSA-5578775),2,-,5.84E-01,9.16E-01,8.34E-01,1.02E+00,,,,,,
Cardiac conduction (R-HSA-5576891),2,-,5.84E-01,9.14E-01,8.32E-01,1.02E+00,,,,,,
Platelet calcium homeostasis (R-HSA-418360),2,-,5.84E-01,9.12E-01,8.30E-01,9.99E-01,,,,,,
Protein ubiquitination (R-HSA-8852135),2,-,5.90E-01,9.14E-01,8.29E-01,9.84E-01,,,,,,
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) (R-HSA-400206),2,+,6.07E-01,9.26E-01,8.37E-01,9.62E-01,,,,,,
PPARA activates gene expression (R-HSA-1989781),2,+,6.07E-01,9.24E-01,8.35E-01,1.09E+00,,,,,,
Recruitment of NuMA to mitotic centrosomes (R-HSA-380320),2,-,6.25E-01,9.30E-01,8.33E-01,1.02E+00,,,,,,
EPHA-mediated growth cone collapse (R-HSA-3928663),2,-,6.31E-01,9.34E-01,8.32E-01,1.00E+00,,,,,,
Sema4D induced cell migration and growth-cone collapse (R-HSA-416572),2,-,6.31E-01,9.32E-01,8.30E-01,1.01E+00,,,,,,
EPH-Ephrin signaling (R-HSA-2682334),2,-,6.31E-01,9.30E-01,8.28E-01,1.01E+00,,,,,,
Sema4D in semaphorin signaling (R-HSA-400685),2,-,6.31E-01,9.28E-01,8.58E-01,1.01E+00,,,,,,
Retrograde transport at the Trans-Golgi-Network (R-HSA-6811440),2,-,6.42E-01,9.23E-01,8.56E-01,1.04E+00,,,,,,
Chondroitin sulfate/dermatan sulfate metabolism (R-HSA-1793185),2,+,6.54E-01,9.30E-01,8.54E-01,1.01E+00,,,,,,
Defective B3GAT3 causes JDSSDHD (R-HSA-3560801),2,+,6.54E-01,9.28E-01,8.53E-01,1.01E+00,,,,,,
Heparan sulfate/heparin (HS-GAG) metabolism (R-HSA-1638091),2,+,6.54E-01,9.26E-01,8.65E-01,1.01E+00,,,,,,
A tetrasaccharide linker sequence is required for GAG synthesis (R-HSA-1971475),2,+,6.54E-01,9.24E-01,8.63E-01,1.00E+00,,,,,,
Defective B3GALT6 causes EDSP2 and SEMDJL1 (R-HSA-4420332),2,+,6.54E-01,9.23E-01,8.62E-01,1.00E+00,,,,,,
Scavenging of heme from plasma (R-HSA-2168880),2,-,6.54E-01,9.21E-01,8.88E-01,1.00E+00,,,,,,
"Defective B4GALT7 causes EDS, progeroid type (R-HSA-3560783)",2,+,6.54E-01,9.19E-01,8.86E-01,9.95E-01,,,,,,
Anchoring fibril formation (R-HSA-2214320),2,-,6.60E-01,9.25E-01,8.84E-01,1.09E+00,,,,,,
GPVI-mediated activation cascade (R-HSA-114604),2,-,6.60E-01,9.23E-01,8.76E-01,1.08E+00,,,,,,
Crosslinking of collagen fibrils (R-HSA-2243919),2,-,6.60E-01,9.21E-01,8.74E-01,1.02E+00,,,,,,
Platelet Adhesion to exposed collagen (R-HSA-75892),2,-,6.60E-01,9.19E-01,8.72E-01,9.50E-01,,,,,,
Processing of Capped Intron-Containing Pre-mRNA (R-HSA-72203),2,+,6.66E-01,9.24E-01,8.71E-01,1.26E+00,,,,,,
mRNA Splicing (R-HSA-72172),2,+,6.66E-01,9.22E-01,8.69E-01,1.10E+00,,,,,,
mRNA Splicing - Major Pathway (R-HSA-72163),2,+,6.66E-01,9.20E-01,8.67E-01,9.99E-01,,,,,,
Meiotic synapsis (R-HSA-1221632),2,+,7.15E-01,9.47E-01,8.66E-01,9.53E-01,,,,,,
Reproduction (R-HSA-1474165),2,+,7.15E-01,9.45E-01,8.64E-01,1.03E+00,,,,,,
Meiosis (R-HSA-1500620),2,+,7.15E-01,9.43E-01,8.72E-01,9.90E-01,,,,,,
GRB2:SOS provides linkage to MAPK signaling for Integrins  (R-HSA-354194),2,-,7.22E-01,9.49E-01,8.84E-01,9.85E-01,,,,,,
Integrin alphaIIb beta3 signaling (R-HSA-354192),2,-,7.22E-01,9.47E-01,8.85E-01,9.46E-01,,,,,,
MAP2K and MAPK activation (R-HSA-5674135),2,-,7.22E-01,9.46E-01,9.20E-01,1.02E+00,,,,,,
Paradoxical activation of RAF signaling by kinase inactive BRAF (R-HSA-6802955),2,-,7.22E-01,9.44E-01,9.27E-01,9.61E-01,,,,,,
Integrin signaling (R-HSA-9006921),2,-,7.22E-01,9.42E-01,9.25E-01,9.98E-01,,,,,,
Signaling by RAS mutants (R-HSA-6802949),2,-,7.22E-01,9.40E-01,9.24E-01,9.96E-01,,,,,,
Signaling by high-kinase activity BRAF mutants (R-HSA-6802948),2,-,7.22E-01,9.38E-01,9.22E-01,1.02E+00,,,,,,
Signaling by moderate kinase activity BRAF mutants (R-HSA-6802946),2,-,7.22E-01,9.36E-01,9.30E-01,2.10E+00,,,,,,
p130Cas linkage to MAPK signaling for integrins (R-HSA-372708),2,-,7.22E-01,9.35E-01,9.30E-01,9.45E-01,,,,,,
G alpha (12/13) signalling events (R-HSA-416482),2,+,7.34E-01,9.35E-01,9.28E-01,9.95E-01,,,,,,
"Cell death signalling via NRAGE, NRIF and NADE (R-HSA-204998)",2,+,7.34E-01,9.33E-01,9.25E-01,9.93E-01,,,,,,
NRAGE signals death through JNK (R-HSA-193648),2,+,7.34E-01,9.31E-01,9.23E-01,9.92E-01,,,,,,
Chylomicron assembly (R-HSA-8963888),2,-,7.40E-01,9.34E-01,9.22E-01,9.42E-01,,,,,,
VLDL assembly (R-HSA-8866423),2,-,7.40E-01,9.32E-01,9.28E-01,1.03E+00,,,,,,
Ion channel transport (R-HSA-983712),2,-,7.72E-01,9.31E-01,9.27E-01,9.90E-01,,,,,,
Signaling by VEGF (R-HSA-194138),2,+,7.84E-01,9.28E-01,9.40E-01,9.94E-01,,,,,,
VEGFA-VEGFR2 Pathway (R-HSA-4420097),2,+,7.84E-01,9.27E-01,9.43E-01,1.02E+00,,,,,,
Mitochondrial tRNA aminoacylation (R-HSA-379726),2,+,8.04E-01,9.20E-01,9.58E-01,1.00E+00,,,,,,
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation (R-HSA-8950505),2,-,8.16E-01,9.21E-01,9.67E-01,9.88E-01,,,,,,
EGFR downregulation (R-HSA-182971),2,-,8.42E-01,9.37E-01,9.66E-01,9.95E-01,,,,,,
Cellular response to heat stress (R-HSA-3371556),2,+,8.49E-01,9.31E-01,9.64E-01,9.99E-01,,,,,,
Amino acid synthesis and interconversion (transamination) (R-HSA-70614),2,-,8.81E-01,9.57E-01,9.63E-01,2.12E+00,,,,,,
Cytosolic sensors of pathogen-associated DNA  (R-HSA-1834949),2,-,9.47E-01,9.85E-01,9.61E-01,3.53E+00,,,,,,
STING mediated induction of host immune responses (R-HSA-1834941),2,-,9.47E-01,9.84E-01,9.60E-01,1.07E+00,,,,,,
IRF3-mediated induction of type I IFN (R-HSA-3270619),2,-,9.47E-01,9.82E-01,9.58E-01,9.60E-01,,,,,,
Post-chaperonin tubulin folding pathway (R-HSA-389977),2,-,9.87E-01,1.00E+00,9.57E-01,1.03E+00,,,,,,
Protein folding (R-HSA-391251),2,-,9.87E-01,1.00E+00,9.55E-01,9.93E-01,,,,,,
Bile acid and bile salt metabolism (R-HSA-194068),2,0,1.00E+00,1.00E+00,9.85E-01,9.37E-01,,,,,,
Degradation of cysteine and homocysteine (R-HSA-1614558),1,+,8.97E-02,1.37E+00,1.51E+00,1.03E+00,,,,,,
Sulfide oxidation to sulfate (R-HSA-1614517),1,+,8.97E-02,1.34E+00,1.47E+00,1.10E+00,,,,,,
Elevation of cytosolic Ca2+ levels (R-HSA-139853),1,-,8.97E-02,1.31E+00,1.44E+00,1.13E+00,,,,,,
Metabolism of folate and pterines (R-HSA-196757),1,+,9.43E-02,1.32E+00,1.40E+00,1.08E+00,,,,,,
Trafficking and processing of endosomal TLR (R-HSA-1679131),1,-,1.01E-01,1.39E+00,1.37E+00,1.03E+00,,,,,,
SUMOylation of transcription cofactors (R-HSA-3899300),1,-,1.06E-01,1.40E+00,1.34E+00,1.02E+00,,,,,,
CDO in myogenesis (R-HSA-375170),1,-,1.12E-01,1.36E+00,1.31E+00,9.90E-01,,,,,,
Signaling by ERBB2 (R-HSA-1227986),1,+,1.12E-01,1.34E+00,1.29E+00,1.76E+00,,,,,,
ERBB2 Regulates Cell Motility (R-HSA-6785631),1,+,1.12E-01,1.31E+00,1.26E+00,1.02E+00,,,,,,
Myogenesis (R-HSA-525793),1,-,1.12E-01,1.29E+00,1.23E+00,9.45E-01,,,,,,
Lysosome Vesicle Biogenesis (R-HSA-432720),1,+,1.20E-01,1.32E+00,1.21E+00,1.74E+00,,,,,,
Anchoring of the basal body to the plasma membrane (R-HSA-5620912),1,-,1.23E-01,1.33E+00,1.21E+00,1.02E+00,,,,,,
Centrosome maturation (R-HSA-380287),1,-,1.23E-01,1.31E+00,1.19E+00,9.43E-01,,,,,,
Loss of proteins required for interphase microtubule organization from the centrosome (R-HSA-380284),1,-,1.23E-01,1.28E+00,1.19E+00,1.56E+00,,,,,,
Recruitment of mitotic centrosome proteins and complexes (R-HSA-380270),1,-,1.23E-01,1.27E+00,1.17E+00,1.01E+00,,,,,,
Loss of Nlp from mitotic centrosomes (R-HSA-380259),1,-,1.23E-01,1.25E+00,1.18E+00,1.05E+00,,,,,,
COPI-independent Golgi-to-ER retrograde traffic (R-HSA-6811436),1,-,1.23E-01,1.23E+00,1.22E+00,9.84E-01,,,,,,
Cilium Assembly (R-HSA-5617833),1,-,1.23E-01,1.21E+00,1.20E+00,9.78E-01,,,,,,
AURKA Activation by TPX2 (R-HSA-8854518),1,-,1.23E-01,1.19E+00,1.18E+00,1.03E+00,,,,,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) (R-HSA-3371497),1,-,1.23E-01,1.17E+00,1.16E+00,9.98E-01,,,,,,
Hyaluronan uptake and degradation (R-HSA-2160916),1,+,1.23E-01,1.16E+00,1.14E+00,1.48E+00,,,,,,
Hyaluronan metabolism (R-HSA-2142845),1,+,1.23E-01,1.14E+00,1.12E+00,9.73E-01,,,,,,
DAP12 interactions (R-HSA-2172127),1,+,1.37E-01,1.23E+00,1.13E+00,1.03E+00,,,,,,
The role of Nef in HIV-1 replication and disease pathogenesis (R-HSA-164952),1,+,1.37E-01,1.21E+00,1.11E+00,9.80E-01,,,,,,
Nef mediated downregulation of MHC class I complex cell surface expression (R-HSA-164940),1,+,1.37E-01,1.20E+00,1.10E+00,1.11E+00,,,,,,
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters (R-HSA-164938),1,+,1.37E-01,1.18E+00,1.08E+00,9.37E-01,,,,,,
Endosomal/Vacuolar pathway (R-HSA-1236977),1,+,1.37E-01,1.17E+00,1.06E+00,9.67E-01,,,,,,
DAP12 signaling (R-HSA-2424491),1,+,1.37E-01,1.15E+00,1.05E+00,1.10E+00,,,,,,
E3 ubiquitin ligases ubiquitinate target proteins (R-HSA-8866654),1,-,1.41E-01,1.14E+00,1.04E+00,1.28E+00,,,,,,
RHO GTPases activate IQGAPs (R-HSA-5626467),1,-,1.44E-01,1.03E+00,1.04E+00,1.43E+00,,,,,,
Phase I - Functionalization of compounds (R-HSA-211945),1,+,1.44E-01,1.02E+00,1.03E+00,1.25E+00,,,,,,
Glycogen storage disease type IV (GBE1) (R-HSA-3878781),1,-,1.54E-01,1.03E+00,1.01E+00,1.02E+00,,,,,,
Glycogen synthesis (R-HSA-3322077),1,-,1.54E-01,1.02E+00,9.79E-01,1.02E+00,,,,,,
Cam-PDE 1 activation (R-HSA-111957),1,-,1.64E-01,9.49E-01,9.80E-01,1.01E+00,,,,,,
Early Phase of HIV Life Cycle (R-HSA-162594),1,+,1.68E-01,9.62E-01,9.82E-01,1.27E+00,,,,,,
Integration of provirus (R-HSA-162592),1,+,1.68E-01,9.53E-01,9.74E-01,1.00E+00,,,,,,
HIV Life Cycle (R-HSA-162587),1,+,1.68E-01,9.45E-01,9.58E-01,9.47E-01,,,,,,
2-LTR circle formation (R-HSA-164843),1,+,1.68E-01,9.37E-01,9.73E-01,1.01E+00,,,,,,
Peroxisomal protein import (R-HSA-9033241),1,-,1.71E-01,9.42E-01,9.64E-01,1.13E+00,,,,,,
Negative regulators of DDX58/IFIH1 signaling (R-HSA-936440),1,+,1.75E-01,9.55E-01,9.88E-01,9.62E-01,,,,,,
Regulation of gap junction activity (R-HSA-191650),1,-,1.75E-01,9.47E-01,1.04E+00,9.58E-01,,,,,,
c-src mediated regulation of Cx43 function and closure of gap junctions (R-HSA-191647),1,-,1.75E-01,9.39E-01,1.03E+00,1.41E+00,,,,,,
DDX58/IFIH1-mediated induction of interferon-alpha/beta (R-HSA-168928),1,+,1.75E-01,9.32E-01,1.02E+00,1.00E+00,,,,,,
RUNX1 regulates expression of components of tight junctions (R-HSA-8935964),1,-,1.75E-01,9.25E-01,9.72E-01,1.01E+00,,,,,,
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 (R-HSA-933543),1,+,1.75E-01,9.17E-01,9.78E-01,1.00E+00,,,,,,
TRAF6 mediated NF-kB activation (R-HSA-933542),1,+,1.75E-01,9.10E-01,9.70E-01,9.95E-01,,,,,,
TRAF6 mediated IRF7 activation (R-HSA-933541),1,+,1.75E-01,9.03E-01,9.63E-01,1.10E+00,,,,,,
TRAF3-dependent IRF activation pathway (R-HSA-918233),1,+,1.75E-01,8.96E-01,9.55E-01,9.66E-01,,,,,,
Ovarian tumor domain proteases (R-HSA-5689896),1,+,1.75E-01,8.90E-01,9.48E-01,1.10E+00,,,,,,
Stimuli-sensing channels (R-HSA-2672351),1,-,1.83E-01,9.14E-01,9.41E-01,1.52E+00,,,,,,
Branched-chain amino acid catabolism (R-HSA-70895),1,+,1.90E-01,9.40E-01,9.39E-01,1.01E+00,,,,,,
Negative regulation of MET activity (R-HSA-6807004),1,-,1.99E-01,9.58E-01,9.32E-01,1.03E+00,,,,,,
Listeria monocytogenes entry into host cells (R-HSA-8876384),1,-,1.99E-01,9.51E-01,9.25E-01,9.85E-01,,,,,,
InlB-mediated entry of Listeria monocytogenes into host cell (R-HSA-8875360),1,-,1.99E-01,9.45E-01,9.44E-01,1.00E+00,,,,,,
Cristae formation (R-HSA-8949613),1,-,2.07E-01,9.64E-01,9.44E-01,1.05E+00,,,,,,
DCC mediated attractive signaling (R-HSA-418885),1,-,2.20E-01,1.00E+00,9.57E-01,1.03E+00,,,,,,
HSF1-dependent transactivation (R-HSA-3371571),1,+,2.24E-01,1.02E+00,9.51E-01,1.02E+00,,,,,,
RET signaling (R-HSA-8853659),1,-,2.43E-01,1.01E+00,9.51E-01,1.10E+00,,,,,,
CD22 mediated BCR regulation (R-HSA-5690714),1,-,2.47E-01,1.02E+00,9.51E-01,1.10E+00,,,,,,
RHO GTPases activate KTN1 (R-HSA-5625970),1,+,2.47E-01,1.01E+00,9.45E-01,1.01E+00,,,,,,
Acetylcholine regulates insulin secretion (R-HSA-399997),1,-,2.52E-01,1.03E+00,9.39E-01,1.09E+00,,,,,,
Signaling by FGFR (R-HSA-190236),1,+,2.52E-01,1.02E+00,9.33E-01,1.00E+00,,,,,,
FGFR2 alternative splicing (R-HSA-6803529),1,+,2.52E-01,1.01E+00,9.27E-01,1.39E+00,,,,,,
Signaling by FGFR2 (R-HSA-5654738),1,+,2.52E-01,1.01E+00,9.22E-01,1.03E+00,,,,,,
p75NTR regulates axonogenesis (R-HSA-193697),1,-,2.57E-01,9.86E-01,9.16E-01,1.00E+00,,,,,,
Axonal growth inhibition (RHOA activation) (R-HSA-193634),1,-,2.57E-01,9.80E-01,9.10E-01,1.02E+00,,,,,,
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) (R-HSA-5619110)",1,-,2.62E-01,9.88E-01,9.36E-01,1.10E+00,,,,,,
SLC transporter disorders (R-HSA-5619102),1,-,2.62E-01,9.83E-01,9.30E-01,1.02E+00,,,,,,
Recycling of bile acids and salts (R-HSA-159418),1,-,2.62E-01,9.77E-01,9.25E-01,1.49E+00,,,,,,
Arachidonic acid metabolism (R-HSA-2142753),1,+,2.62E-01,9.72E-01,9.19E-01,1.02E+00,,,,,,
Synthesis of bile acids and bile salts (R-HSA-192105),1,+,2.62E-01,9.66E-01,9.10E-01,9.94E-01,,,,,,
"Transport of vitamins, nucleosides, and related molecules (R-HSA-425397)",1,-,2.62E-01,9.61E-01,9.05E-01,1.25E+00,,,,,,
Synthesis of bile acids and bile salts via 27-hydroxycholesterol (R-HSA-193807),1,+,2.62E-01,9.56E-01,9.00E-01,1.02E+00,,,,,,
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol (R-HSA-193368),1,+,2.62E-01,9.51E-01,8.95E-01,9.34E-01,,,,,,
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR) (R-HSA-5619058)",1,-,2.62E-01,9.46E-01,8.93E-01,9.96E-01,,,,,,
RA biosynthesis pathway (R-HSA-5365859),1,+,2.62E-01,9.40E-01,8.88E-01,1.13E+00,,,,,,
Transport of organic anions (R-HSA-879518),1,-,2.62E-01,9.35E-01,8.83E-01,1.02E+00,,,,,,
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) (R-HSA-2162123),1,+,2.62E-01,9.31E-01,8.78E-01,1.46E+00,,,,,,
Signaling by Retinoic Acid (R-HSA-5362517),1,+,2.62E-01,9.26E-01,8.91E-01,9.92E-01,,,,,,
HDL remodeling (R-HSA-8964058),1,-,2.62E-01,9.21E-01,8.89E-01,1.59E+00,,,,,,
Synthesis of bile acids and bile salts via 24-hydroxycholesterol (R-HSA-193775),1,+,2.62E-01,9.16E-01,8.85E-01,9.65E-01,,,,,,
Protein methylation (R-HSA-8876725),1,+,2.67E-01,9.19E-01,9.05E-01,1.02E+00,,,,,,
Glycogen breakdown (glycogenolysis) (R-HSA-70221),1,-,2.67E-01,9.15E-01,9.01E-01,1.01E+00,,,,,,
Glycogen storage disease type II (GAA) (R-HSA-5357609),1,-,2.67E-01,9.10E-01,8.96E-01,1.01E+00,,,,,,
PERK regulates gene expression (R-HSA-381042),1,+,2.83E-01,9.21E-01,8.92E-01,9.93E-01,,,,,,
ATF4 activates genes (R-HSA-380994),1,+,2.83E-01,9.16E-01,8.87E-01,1.02E+00,,,,,,
KSRP (KHSRP) binds and destabilizes mRNA (R-HSA-450604),1,+,2.83E-01,9.12E-01,8.83E-01,9.42E-01,,,,,,
Advanced glycosylation endproduct receptor signaling (R-HSA-879415),1,+,2.88E-01,9.16E-01,8.79E-01,9.56E-01,,,,,,
GPCR ligand binding (R-HSA-500792),1,-,2.99E-01,9.37E-01,8.74E-01,1.01E+00,,,,,,
Peptide ligand-binding receptors (R-HSA-375276),1,-,2.99E-01,9.32E-01,8.70E-01,9.51E-01,,,,,,
Class A/1 (Rhodopsin-like receptors) (R-HSA-373076),1,-,2.99E-01,9.28E-01,8.66E-01,9.70E-01,,,,,,
Formyl peptide receptors bind formyl peptides and many other ligands (R-HSA-444473),1,-,2.99E-01,9.24E-01,8.62E-01,9.66E-01,,,,,,
Vitamins B6 activation to pyridoxal phosphate (R-HSA-964975),1,+,2.99E-01,9.19E-01,8.66E-01,1.01E+00,,,,,,
Regulation of PTEN localization (R-HSA-8948747),1,+,3.04E-01,6.78E-01,6.40E-01,9.90E-01,,,,,,
TBC/RABGAPs (R-HSA-8854214),1,-,3.04E-01,6.76E-01,6.38E-01,9.99E-01,,,,,,
SUMOylation of DNA damage response and repair proteins (R-HSA-3108214),1,+,3.04E-01,6.74E-01,6.53E-01,1.13E+00,,,,,,
SUMOylation of ubiquitinylation proteins (R-HSA-3232142),1,+,3.04E-01,6.71E-01,6.51E-01,1.00E+00,,,,,,
Regulation of RUNX1 Expression and Activity (R-HSA-8934593),1,+,3.04E-01,6.69E-01,6.61E-01,9.90E-01,,,,,,
Regulation of TP53 Activity through Acetylation (R-HSA-6804758),1,+,3.04E-01,6.67E-01,6.58E-01,1.23E+00,,,,,,
Regulation of TP53 Activity (R-HSA-5633007),1,+,3.04E-01,6.65E-01,6.78E-01,9.35E-01,,,,,,
Rab regulation of trafficking (R-HSA-9007101),1,-,3.04E-01,6.63E-01,6.76E-01,1.25E+00,,,,,,
Scavenging by Class H Receptors (R-HSA-3000497),1,-,3.21E-01,6.82E-01,6.67E-01,1.00E+00,,,,,,
Scavenging by Class B Receptors (R-HSA-3000471),1,-,3.21E-01,6.80E-01,6.66E-01,1.00E+00,,,,,,
Platelet sensitization by LDL (R-HSA-432142),1,-,3.21E-01,6.77E-01,6.96E-01,9.59E-01,,,,,,
Regulation of TLR by endogenous ligand (R-HSA-5686938),1,-,3.21E-01,6.75E-01,7.06E-01,1.23E+00,,,,,,
Chylomicron remodeling (R-HSA-8963901),1,-,3.21E-01,6.73E-01,7.04E-01,9.62E-01,,,,,,
VLDL clearance (R-HSA-8964046),1,-,3.21E-01,6.71E-01,7.02E-01,1.01E+00,,,,,,
LDL remodeling (R-HSA-8964041),1,-,3.21E-01,6.69E-01,7.12E-01,1.01E+00,,,,,,
Chylomicron clearance (R-HSA-8964026),1,-,3.21E-01,6.67E-01,7.10E-01,1.45E+00,,,,,,
HDL clearance (R-HSA-8964011),1,-,3.27E-01,6.75E-01,7.08E-01,1.10E+00,,,,,,
Glycosphingolipid metabolism (R-HSA-1660662),1,+,3.33E-01,6.83E-01,7.16E-01,9.75E-01,,,,,,
Sphingolipid metabolism (R-HSA-428157),1,+,3.33E-01,6.81E-01,7.14E-01,1.10E+00,,,,,,
CRMPs in Sema3A signaling (R-HSA-399956),1,+,3.39E-01,6.88E-01,7.12E-01,1.01E+00,,,,,,
Regulation of HSF1-mediated heat shock response (R-HSA-3371453),1,-,3.45E-01,6.98E-01,7.09E-01,9.37E-01,,,,,,
Toll Like Receptor 9 (TLR9) Cascade (R-HSA-168138),1,+,3.51E-01,7.02E-01,7.07E-01,1.10E+00,,,,,,
Ion transport by P-type ATPases (R-HSA-936837),1,+,3.57E-01,7.08E-01,7.05E-01,1.01E+00,,,,,,
Reduction of cytosolic Ca++ levels (R-HSA-418359),1,+,3.57E-01,7.06E-01,7.03E-01,1.01E+00,,,,,,
Insulin effects increased synthesis of Xylulose-5-Phosphate (R-HSA-163754),1,-,3.69E-01,7.24E-01,7.01E-01,9.95E-01,,,,,,
"Formation of the active cofactor, UDP-glucuronate (R-HSA-173599)",1,-,3.95E-01,7.59E-01,6.99E-01,9.86E-01,,,,,,
Glucuronidation (R-HSA-156588),1,-,3.95E-01,7.56E-01,6.97E-01,9.69E-01,,,,,,
HS-GAG biosynthesis (R-HSA-2022928),1,+,4.08E-01,7.75E-01,6.96E-01,9.58E-01,,,,,,
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS (R-HSA-3656253)",1,+,4.08E-01,7.73E-01,6.98E-01,1.01E+00,,,,,,
Defective EXT2 causes exostoses 2 (R-HSA-3656237),1,+,4.08E-01,7.71E-01,7.22E-01,1.00E+00,,,,,,
HS-GAG degradation (R-HSA-2024096),1,+,4.08E-01,7.69E-01,7.20E-01,1.08E+00,,,,,,
Amino acid transport across the plasma membrane (R-HSA-352230),1,-,4.42E-01,8.06E-01,7.30E-01,9.98E-01,,,,,,
Transport of inorganic cations/anions and amino acids/oligopeptides (R-HSA-425393),1,-,4.42E-01,8.03E-01,7.28E-01,9.53E-01,,,,,,
Creatine metabolism (R-HSA-71288),1,-,4.49E-01,8.10E-01,7.54E-01,1.07E+00,,,,,,
Clearance of Nuclear Envelope Membranes from Chromatin (R-HSA-2993913),1,-,4.56E-01,8.18E-01,7.52E-01,1.00E+00,,,,,,
Nuclear Envelope Breakdown (R-HSA-2980766),1,-,4.56E-01,8.16E-01,7.77E-01,9.90E-01,,,,,,
DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586),1,-,4.56E-01,8.14E-01,7.75E-01,1.24E+00,,,,,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF) (R-HSA-2559584),1,-,4.56E-01,8.11E-01,7.83E-01,9.46E-01,,,,,,
Breakdown of the nuclear lamina (R-HSA-352238),1,-,4.56E-01,8.09E-01,7.81E-01,1.01E+00,,,,,,
Nuclear Envelope Reassembly (R-HSA-2995410),1,-,4.56E-01,8.07E-01,7.79E-01,1.04E+00,,,,,,
Depolymerisation of the Nuclear Lamina (R-HSA-4419969),1,-,4.56E-01,8.05E-01,7.85E-01,1.08E+00,,,,,,
Initiation of Nuclear Envelope Reformation (R-HSA-2995383),1,-,4.56E-01,8.03E-01,7.86E-01,9.98E-01,,,,,,
Synthesis of active ubiquitin: roles of E1 and E2 enzymes (R-HSA-8866652),1,+,4.77E-01,8.26E-01,7.84E-01,1.01E+00,,,,,,
Glyoxylate metabolism and glycine degradation (R-HSA-389661),1,-,4.77E-01,8.24E-01,7.82E-01,9.76E-01,,,,,,
Processing of DNA double-strand break ends (R-HSA-5693607),1,-,5.15E-01,8.59E-01,7.80E-01,9.95E-01,,,,,,
DNA Double Strand Break Response (R-HSA-5693606),1,-,5.15E-01,8.57E-01,7.78E-01,1.10E+00,,,,,,
G2/M DNA damage checkpoint (R-HSA-69473),1,-,5.15E-01,8.55E-01,7.76E-01,1.62E+00,,,,,,
SUMOylation of transcription factors (R-HSA-3232118),1,-,5.15E-01,8.53E-01,7.77E-01,1.22E+00,,,,,,
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) (R-HSA-5693567),1,-,5.15E-01,8.50E-01,7.75E-01,9.91E-01,,,,,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks (R-HSA-5693565),1,-,5.15E-01,8.48E-01,7.73E-01,1.20E+00,,,,,,
Homology Directed Repair (R-HSA-5693538),1,-,5.15E-01,8.46E-01,7.72E-01,1.12E+00,,,,,,
RNA Polymerase I Transcription (R-HSA-73864),1,-,5.30E-01,8.65E-01,7.70E-01,9.92E-01,,,,,,
RNA Polymerase I Transcription Termination (R-HSA-73863),1,-,5.30E-01,8.63E-01,7.68E-01,1.10E+00,,,,,,
Senescence-Associated Secretory Phenotype (SASP) (R-HSA-2559582),1,-,5.38E-01,8.71E-01,7.66E-01,1.09E+00,,,,,,
Pyruvate metabolism (R-HSA-70268),1,+,5.69E-01,9.00E-01,7.64E-01,1.22E+00,,,,,,
Type I hemidesmosome assembly (R-HSA-446107),1,+,5.77E-01,9.07E-01,7.88E-01,9.47E-01,,,,,,
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion (R-HSA-399955),1,-,5.85E-01,9.11E-01,7.87E-01,1.02E+00,,,,,,
mRNA Splicing - Minor Pathway (R-HSA-72165),1,-,5.93E-01,9.11E-01,7.85E-01,9.90E-01,,,,,,
Interleukin-23 signaling (R-HSA-9020933),1,+,6.01E-01,9.19E-01,7.83E-01,1.07E+00,,,,,,
Role of ABL in ROBO-SLIT signaling (R-HSA-428890),1,+,6.09E-01,9.21E-01,7.81E-01,9.78E-01,,,,,,
Formation of annular gap junctions (R-HSA-196025),1,-,6.09E-01,9.19E-01,7.79E-01,9.42E-01,,,,,,
Gap junction degradation (R-HSA-190873),1,-,6.09E-01,9.17E-01,7.78E-01,1.03E+00,,,,,,
Gap junction trafficking (R-HSA-190828),1,-,6.09E-01,9.15E-01,7.76E-01,1.36E+00,,,,,,
Butyrophilin (BTN) family interactions (R-HSA-8851680),1,+,6.34E-01,9.23E-01,7.79E-01,1.06E+00,,,,,,
Peptide hormone metabolism (R-HSA-2980736),1,+,6.85E-01,9.37E-01,7.77E-01,9.99E-01,,,,,,
Estrogen-dependent gene expression (R-HSA-9018519),1,+,6.85E-01,9.35E-01,8.16E-01,1.43E+00,,,,,,
ESR-mediated signaling (R-HSA-8939211),1,+,6.85E-01,9.33E-01,8.33E-01,1.00E+00,,,,,,
Metabolism of Angiotensinogen to Angiotensins (R-HSA-2022377),1,+,6.85E-01,9.31E-01,8.32E-01,1.00E+00,,,,,,
tRNA processing (R-HSA-72306),1,-,6.94E-01,9.41E-01,8.29E-01,1.71E+00,,,,,,
tRNA modification in the nucleus and cytosol (R-HSA-6782315),1,-,6.94E-01,9.39E-01,8.27E-01,9.89E-01,,,,,,
Mitochondrial protein import (R-HSA-1268020),1,-,7.03E-01,9.45E-01,8.26E-01,1.02E+00,,,,,,
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) (R-HSA-3656244),1,-,7.29E-01,9.41E-01,8.24E-01,1.01E+00,,,,,,
Defective ST3GAL3 causes MCT12 and EIEE15 (R-HSA-3656243),1,-,7.29E-01,9.39E-01,8.27E-01,1.02E+00,,,,,,
Defective CHST6 causes MCDC1 (R-HSA-3656225),1,-,7.29E-01,9.37E-01,8.48E-01,1.02E+00,,,,,,
Keratan sulfate/keratin metabolism (R-HSA-1638074),1,-,7.29E-01,9.35E-01,8.65E-01,9.96E-01,,,,,,
Keratan sulfate degradation (R-HSA-2022857),1,-,7.29E-01,9.34E-01,8.63E-01,1.10E+00,,,,,,
Keratan sulfate biosynthesis (R-HSA-2022854),1,-,7.29E-01,9.32E-01,8.62E-01,9.88E-01,,,,,,
Other interleukin signaling (R-HSA-449836),1,-,7.38E-01,9.34E-01,8.60E-01,1.19E+00,,,,,,
Interleukin-6 family signaling (R-HSA-6783589),1,+,7.56E-01,9.44E-01,8.58E-01,1.10E+00,,,,,,
Intra-Golgi traffic (R-HSA-6811438),1,-,7.56E-01,9.42E-01,8.56E-01,1.09E+00,,,,,,
Signaling by SCF-KIT (R-HSA-1433557),1,+,7.56E-01,9.41E-01,8.73E-01,9.88E-01,,,,,,
Interleukin-35 Signalling (R-HSA-8984722),1,+,7.56E-01,9.39E-01,8.71E-01,9.84E-01,,,,,,
Downstream signal transduction (R-HSA-186763),1,+,7.56E-01,9.37E-01,8.70E-01,9.99E-01,,,,,,
Interleukin-21 signaling (R-HSA-9020958),1,+,7.56E-01,9.36E-01,8.83E-01,9.86E-01,,,,,,
Interleukin-27 signaling (R-HSA-9020956),1,+,7.56E-01,9.34E-01,8.82E-01,9.39E-01,,,,,,
NOTCH3 Intracellular Domain Regulates Transcription (R-HSA-9013508),1,+,7.56E-01,9.32E-01,8.80E-01,1.03E+00,,,,,,
Interleukin-2 family signaling (R-HSA-451927),1,+,7.56E-01,9.30E-01,8.78E-01,9.83E-01,,,,,,
Interleukin-6 signaling (R-HSA-1059683),1,+,7.56E-01,9.29E-01,8.77E-01,1.05E+00,,,,,,
Signaling by FGFR in disease (R-HSA-1226099),1,+,7.56E-01,9.27E-01,8.75E-01,1.01E+00,,,,,,
Interleukin-9 signaling (R-HSA-8985947),1,+,7.56E-01,9.25E-01,8.84E-01,9.83E-01,,,,,,
Interleukin-20 family signaling (R-HSA-8854691),1,+,7.56E-01,9.24E-01,8.83E-01,1.21E+00,,,,,,
Growth hormone receptor signaling (R-HSA-982772),1,+,7.56E-01,9.22E-01,8.85E-01,9.83E-01,,,,,,
FGFR1 mutant receptor activation (R-HSA-1839124),1,+,7.56E-01,9.20E-01,8.84E-01,1.77E+00,,,,,,
Signaling by cytosolic FGFR1 fusion mutants (R-HSA-1839117),1,+,7.56E-01,9.19E-01,8.82E-01,1.67E+00,,,,,,
Signaling by FGFR1 in disease (R-HSA-5655302),1,+,7.56E-01,9.17E-01,8.80E-01,1.02E+00,,,,,,
Signaling by NOTCH3 (R-HSA-9012852),1,+,7.56E-01,9.15E-01,8.79E-01,1.00E+00,,,,,,
COPI-dependent Golgi-to-ER retrograde traffic (R-HSA-6811434),1,+,7.83E-01,9.31E-01,8.77E-01,1.09E+00,,,,,,
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion (R-HSA-381676),1,-,7.92E-01,9.32E-01,8.75E-01,9.94E-01,,,,,,
DARPP-32 events (R-HSA-180024),1,-,7.92E-01,9.30E-01,8.74E-01,9.95E-01,,,,,,
Glucagon signaling in metabolic regulation (R-HSA-163359),1,-,7.92E-01,9.29E-01,8.68E-01,1.34E+00,,,,,,
Factors involved in megakaryocyte development and platelet production (R-HSA-983231),1,-,7.92E-01,9.27E-01,8.67E-01,9.91E-01,,,,,,
PKA activation (R-HSA-163615),1,-,7.92E-01,9.25E-01,8.65E-01,1.00E+00,,,,,,
Aquaporin-mediated transport (R-HSA-445717),1,-,7.92E-01,9.24E-01,8.64E-01,1.27E+00,,,,,,
PKA-mediated phosphorylation of CREB (R-HSA-111931),1,-,7.92E-01,9.22E-01,8.62E-01,1.17E+00,,,,,,
Vasopressin regulates renal water homeostasis via Aquaporins (R-HSA-432040),1,-,7.92E-01,9.21E-01,8.60E-01,9.53E-01,,,,,,
ROBO receptors bind AKAP5 (R-HSA-9010642),1,-,7.92E-01,9.19E-01,8.59E-01,9.49E-01,,,,,,
PKA activation in glucagon signalling (R-HSA-164378),1,-,7.92E-01,9.17E-01,8.80E-01,9.96E-01,,,,,,
HDL assembly (R-HSA-8963896),1,+,8.10E-01,9.23E-01,8.93E-01,9.92E-01,,,,,,
Formation of Fibrin Clot (Clotting Cascade) (R-HSA-140877),1,+,8.10E-01,9.21E-01,9.11E-01,9.89E-01,,,,,,
Intrinsic Pathway of Fibrin Clot Formation (R-HSA-140837),1,+,8.10E-01,9.19E-01,9.10E-01,9.80E-01,,,,,,
Methionine salvage pathway (R-HSA-1237112),1,-,8.19E-01,9.19E-01,9.08E-01,9.32E-01,,,,,,
Regulation of Complement cascade (R-HSA-977606),1,+,8.28E-01,9.28E-01,9.06E-01,9.64E-01,,,,,,
Complement cascade (R-HSA-166658),1,+,8.28E-01,9.26E-01,9.05E-01,9.77E-01,,,,,,
Cargo concentration in the ER (R-HSA-5694530),1,+,8.28E-01,9.24E-01,9.03E-01,9.84E-01,,,,,,
RUNX2 regulates osteoblast differentiation (R-HSA-8940973),1,+,8.46E-01,9.40E-01,9.02E-01,1.09E+00,,,,,,
Dermatan sulfate biosynthesis (R-HSA-2022923),1,-,8.46E-01,9.39E-01,9.00E-01,9.33E-01,,,,,,
CS/DS degradation (R-HSA-2024101),1,-,8.46E-01,9.37E-01,8.99E-01,9.96E-01,,,,,,
RUNX2 regulates bone development (R-HSA-8941326),1,+,8.46E-01,9.36E-01,8.97E-01,1.12E+00,,,,,,
Defective CHSY1 causes TPBS (R-HSA-3595177),1,-,8.46E-01,9.34E-01,8.95E-01,9.90E-01,,,,,,
"Defective CHST14 causes EDS, musculocontractural type (R-HSA-3595174)",1,-,8.46E-01,9.33E-01,8.94E-01,1.07E+00,,,,,,
Defective CHST3 causes SEDCJD (R-HSA-3595172),1,-,8.46E-01,9.31E-01,8.92E-01,1.00E+00,,,,,,
Chondroitin sulfate biosynthesis (R-HSA-2022870),1,-,8.46E-01,9.29E-01,8.91E-01,9.94E-01,,,,,,
Fatty acyl-CoA biosynthesis (R-HSA-75105),1,-,8.93E-01,9.66E-01,8.89E-01,9.86E-01,,,,,,
Regulation of cholesterol biosynthesis by SREBP (SREBF) (R-HSA-1655829),1,-,8.93E-01,9.64E-01,8.88E-01,9.89E-01,,,,,,
Vitamin B5 (pantothenate) metabolism (R-HSA-199220),1,-,8.93E-01,9.63E-01,8.86E-01,1.05E+00,,,,,,
Activation of gene expression by SREBF (SREBP) (R-HSA-2426168),1,-,8.93E-01,9.61E-01,9.23E-01,1.12E+00,,,,,,
ChREBP activates metabolic gene expression (R-HSA-163765),1,-,8.93E-01,9.60E-01,9.31E-01,9.91E-01,,,,,,
Glutathione conjugation (R-HSA-156590),1,-,9.02E-01,9.64E-01,9.29E-01,9.77E-01,,,,,,
Glutathione synthesis and recycling (R-HSA-174403),1,-,9.02E-01,9.62E-01,9.28E-01,1.00E+00,,,,,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain (R-HSA-6804115),1,+,9.11E-01,9.67E-01,9.29E-01,1.04E+00,,,,,,
TP53 Regulates Transcription of Cell Cycle Genes (R-HSA-6791312),1,+,9.11E-01,9.66E-01,9.27E-01,1.58E+00,,,,,,
Virus Assembly and Release (R-HSA-168268),1,-,9.20E-01,9.71E-01,9.26E-01,1.09E+00,,,,,,
ATF6 (ATF6-alpha) activates chaperones (R-HSA-381033),1,-,9.20E-01,9.70E-01,9.25E-01,9.81E-01,,,,,,
ATF6 (ATF6-alpha) activates chaperone genes (R-HSA-381183),1,-,9.20E-01,9.68E-01,9.23E-01,9.88E-01,,,,,,
Assembly of Viral Components at the Budding Site (R-HSA-168316),1,-,9.20E-01,9.67E-01,9.27E-01,1.32E+00,,,,,,
Triglyceride metabolism (R-HSA-8979227),1,+,9.49E-01,9.82E-01,9.28E-01,1.30E+00,,,,,,
Triglyceride catabolism (R-HSA-163560),1,+,9.49E-01,9.81E-01,9.41E-01,9.98E-01,,,,,,
Mitochondrial translation (R-HSA-5368287),1,+,9.58E-01,9.86E-01,9.43E-01,1.00E+00,,,,,,
Mitochondrial translation elongation (R-HSA-5389840),1,+,9.58E-01,9.84E-01,9.50E-01,9.77E-01,,,,,,
Surfactant metabolism (R-HSA-5683826),1,-,9.67E-01,9.91E-01,9.64E-01,9.27E-01,,,,,,
Fibronectin matrix formation (R-HSA-1566977),1,+,9.67E-01,9.89E-01,9.62E-01,9.99E-01,,,,,,
Transcriptional activation of mitochondrial biogenesis (R-HSA-2151201),1,+,9.86E-01,1.00E+00,9.61E-01,1.09E+00,,,,,,
Signaling by Non-Receptor Tyrosine Kinases (R-HSA-9006927),1,-,9.95E-01,1.01E+00,9.59E-01,9.86E-01,,,,,,
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases (R-HSA-8849471)",1,-,9.95E-01,1.00E+00,9.58E-01,9.82E-01,,,,,,
Signaling by PTK6 (R-HSA-8848021),1,-,9.95E-01,1.00E+00,9.56E-01,1.28E+00,,,,,,
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components (R-HSA-446388),1,-,9.95E-01,1.00E+00,9.64E-01,1.04E+00,,,,,,
Localization of the PINCH-ILK-PARVIN complex to focal adhesions (R-HSA-446343),1,-,9.95E-01,1.00E+00,9.80E-01,1.10E+00,,,,,,
GAB1 signalosome (R-HSA-180292),1,-,9.95E-01,9.98E-01,9.82E-01,9.74E-01,,,,,,
